Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primatesArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accompanied Blood clinical investigation Coverage COVID-19 COVID-19 pandemic COVID-19 vaccine cytokine release Diseases effective effort elicit Gam-COVID-Vac Health heterologous prime-boost IgA antibody IgG immune response Immunity immunization immunogenic immunogenicity Infection intranasal intranasal vaccine. intranasally K18-hACE2 transgenic mice less lung immunopathology mice mononuclear cell Mortality mucosal nasal mucosa neutralizing antibody non-human primate pandemic Peripheral blood Prevent proliferation protective immunity provided revaccination robust SARS-CoV-2 SARS-COV-2 infection SARSCoV-2 serum Sputnik V systemic and local the vaccine Transmission vaccination Vaccination strategy Vaccine vaccine candidate variants of concern virus virus infection virus spread [DOI] 10.1080/22221751.2022.2119169 PMC 바로가기
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] antibodies antibody Antigen association Asymptomatic asymptomatic individual asymptomatic infection Betacoronavirus betacoronavirus Community convalescent correlated COVID-19 COVID-19 severity develop diagnosed diagnostics disease severity domains Epitopes Evidence evidence of finding FIVE five groups HKU1 Hospitalization IgG IgGs Immunity immunogenic immunogenic peptide individual Infection less MERS-CoV nucleocapsid protein Nucleocapsid proteins OC43 participant pathogenic pathogenic mechanisms peptide peptide array peptides pilot study predicted Protein RBDs reaction Receptor binding domain Region repertoire SARS-CoV RBD SARS-CoV RBDs SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes seroconverted Seroprevalence seroprevalence. severity severity of COVID-19 symptomatic symptomatic COVID-19 symptomatic infection therapeutic therapeutic antibodies Vaccines Viral with COVID-19 without symptoms [DOI] 10.1080/21505594.2022.2073025 PMC 바로가기 [Article Type] Article
Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunityArticle Published on 2022-11-012022-11-15 Journal: Annals of allergy, asthma & immunology : official [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] antibody Antibody Response Autoimmune clinical trial clinician Combination Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine criteria detectable Diagnosis Evidence Factor healthy controls immune immune dysregulation Immunity immunodeficiency immunogenic individuals literature Messenger RNA Patient performed reactogenicity response Safe Safety SARS-CoV-2 Serious Adverse Events subjects T cell response vaccination Vaccinations Vaccine [DOI] 10.1016/j.anai.2022.06.009 PMC 바로가기
Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet lightArticle Published on 2022-11-012022-11-15 Journal: Archives of Virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Antigen antigenic antigenic variant can be used COVID-19 diagnostic disease effective Effectiveness immunization immunogenic inactivated Inactivated vaccine inactivation induce mice morphology physical Protective reducing mortality SARS-CoV-2 Spread Treatment ultraviolet ultraviolet light Vaccine virus inactivation virus stock virus-neutralizing antibody [DOI] 10.1007/s00705-022-05530-7 PMC 바로가기
Modular nanoarray vaccine for SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: Nanomedicine : nanotechnology, biology, and medici [Category] SARS, 변종, 진단, [키워드] B-cell epitope children complementary COVID-19 pandemic defined delta variant DNA effective epitope generate Gold nanoparticle IgG immune response immunized immunocompromised individuals immunogen immunogenic inactive mice mRNA neutralizing antibody PADRE peptide pregnant women probe recombinant proteins resulting SARS-CoV-2 spike glycoprotein time-consuming Vaccine Vaccine development vaccine platform Variants of concerns (VOC). virus neutralizing titer virus-like particles viruses VoC while wildtype [DOI] 10.1016/j.nano.2022.102604 PMC 바로가기
Bioinformatics pipeline unveils genetic variability to synthetic vaccine design for Indian SARS-CoV-2 genomesArticle Published on 2022-11-012022-11-15 Journal: International immunopharmacology [Category] SARS, 치료기술, 치료제, [키워드] aligned amino acid change antigenic antigenic epitopes B-cell epitope bioinformatics bioinformatics pipeline can be used clade clades conserved conserved regions criteria epitope Evolution genetic variability genomic HLA allele identify immunogenic MAFFT MHC-I MHC-II Multiple sequence alignment Mutation Nextstrain Non-synonymous Non-Synonymous Signature SNP performed Phylogenetic analysis primer probe Protein Region regions reported resulting SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 pandemic selected SNP SNPs T-cell T-cell epitope T-cell epitopes T-cell epitopes. unique Vaccine Vaccine design virus virus detection virus genome [DOI] 10.1016/j.intimp.2022.109224 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variantsArticle Published on 2022-10-302022-11-15 Journal: Biochemical and Biophysical Research Communication [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] affinities antibodies antibody Antibody binding antibody escape appear approach approved binding affinity binding free energy cause Coverage COVID19 decrease Effect evaluate globe hotspot immune evasion immunogenic Immunogenic hotspot immunoinformatics K417N monoclonal antibody mutant Mutation mutations omicron Omicron variant Omicron variants Omicron variants. Point mutation RBD mutation RBD-specific antibody recent Receptor binding domain reduce reduction in REGN10987 residue selection pressure significantly single mutation the binding affinity therapeutic vaccination variants [DOI] 10.1016/j.bbrc.2022.08.050 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Towards the development of an epitope-focused vaccine for SARS-CoV-2Article Published on 2022-10-262022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibodies BALB/c mice CD8+ T cell COVID-19 deficiency disease DNA effective effort epitope expression hamster hamsters IFN-γ immunogenic immunogenicity data in vitro Inclusion mice Mortality pandemic coronavirus peptide peptides platform predicted prevalent Protein Proteins RBD peptide regions reported RNA Safe SARS-CoV-2 SARS-CoV-2 virus sequence specific IgG antibody spread of COVID-19 starting point subcutaneous administration Support tested the Spike Vaccine Vaccine development vaccine. Vaccines variant variants of concern Viral vector virus [DOI] 10.1016/j.vaccine.2022.09.059 PMC 바로가기